UK authority blames hospital for Pantak fault
This article was originally published in Clinica
The UK's device regulatory body, the Medical Devices Agency (MDA), has warned UK hospitals using the Pantak Therapax DXT 300 orthovoltage radiotherapy unit that under-dosing can occur at the field periphery, though the company making the device is not at fault. The regulator blames a poor quality control regime, which did not detect misalignment problems.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.